In addition to mutations, overexpression of EZH2 has also been observed in various solid tumors, including bladder cancer,11,12 gastric cancer,13 prostate cancer,14 melanoma,15,16 and breast cancer.17,18 The aberrant expression of EZH2 has been found associated with the disease progress in breast cancer, and leads to higher risk of invasion and metastasis in both prostate and breast cancers.14,17,18. Here, EZH2 is linked to breast carcinoma.